Achillion Pharmaceuticals (ACHN) : Turner Investments reduced its stake in Achillion Pharmaceuticals by 5.65% during the most recent quarter end. The investment management company now holds a total of 859,560 shares of Achillion Pharmaceuticals which is valued at $7 Million after selling 51,450 shares in Achillion Pharmaceuticals , the firm said in a disclosure report filed with the SEC on May 13, 2016.Achillion Pharmaceuticals makes up approximately 1.93% of Turner Investments’s portfolio.
Other Hedge Funds, Including , Sabby Management added ACHN to its portfolio by purchasing 105,648 company shares during the most recent quarter which is valued at $859,975. Achillion Pharmaceuticals makes up approx 0.30% of Sabby Management’s portfolio. Engineers Gate Manager Lp sold out all of its stake in ACHN during the most recent quarter. The investment firm sold 15,400 shares of ACHN which is valued $125,356. Ausdal Financial Partners sold out all of its stake in ACHN during the most recent quarter. The investment firm sold 5,000 shares of ACHN which is valued $39,600.Schwab Charles Investment Management Inc boosted its stake in ACHN in the latest quarter, The investment management firm added 8,011 additional shares and now holds a total of 391,106 shares of Achillion Pharmaceuticals which is valued at $3.1 Million. Nisa Investment Advisors L.l.c. added ACHN to its portfolio by purchasing 2,300 company shares during the most recent quarter which is valued at $19,665.
Achillion Pharmaceuticals opened for trading at $8.94 and hit $9.15 on the upside on Wednesday, eventually ending the session at $9.05, with a gain of 1.80% or 0.16 points. The heightened volatility saw the trading volume jump to 13,21,690 shares. Company has a market cap of $1,237 M.
On the company’s financial health, Achillion Pharmaceuticals reported $-0.13 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on May 3, 2016. Analyst had a consensus of $-0.14.During the same quarter in the previous year, the company posted $-0.17 EPS.
Many Wall Street Analysts have commented on Achillion Pharmaceuticals. Robert W. Baird Upgraded Achillion Pharmaceuticals on Feb 26, 2016 to ” Outperform”, Price Target of the shares are set at $10.Shares were Reiterated by Maxim Group on Feb 25, 2016 to “Buy” and Lowered the Price Target to $ 8 from a previous price target of $11 .
Achillion Pharmaceuticals Inc. is a biopharmaceutical company. The Company’s primary business is to discover develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on developing short-duration combination therapies for the treatment of chronic hepatitis C virus or HCV infection that are once-daily and ribavirin-free. The Company is advancing several combination regimens including ACH-3102 a NS5A inhibitor which is under Phase II clinical development ACH-3422 a NS5B nucleotide polymerase inhibitor which is under Phase I clinical development and Sovaprevir a NS3 protease inhibitor which is under Phase II clinical development.